1. Rubie H, Benoit Y, Behar C, Lutz P, Maurus R, Philippe N, Plouvier E, Robert A, Sauveur E, Solbu G, Suciu S, Otten J . Treatment of standard risk (SR) acute lymphoblastic leukemia (ALL) with the BFM protocol with or without cyclophosphamide: preliminary results of a randomized trial (EORTC nr 58831). SIOP XX Meeting, Trondheim, Norway, 22–26 August 1988
2. Benoit Y, Boilletot A, Francotte N, Hoyoux C, Marguerite G, Philippe N, Souillet G, Thyss A, Solbu G, Suciu S, Otten J . Treatment of medium and high risk (M-HR) acute lymphoblastic leukemia (ALL) with or without radiotherapy (RXT): results of a randomized trial (EORTC nr 58832). SIOP XX Meeting, Trondheim, Norway, 22–26 August 1988
3. Millot F, Suciu S, Philippe N, Benoit Y, Nelken B, Uyttebroeck A, Mechinaud F, Vilmer E, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behar C, Plantaz D, Dresse MF, Philippet P, Waterkeyn C, Otten J . Value of high dose Ara-C during the interval-therapy of a BFM like protocol in increased risk ALL and NHL stage III and IV patients: results of the EORTC 58881 trial Blood 1999 94: (Suppl. 1) (Abstr. 1700)
4. Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Mechinaud F, Vilmer E, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behar C, Plantaz D, Dresse MF, Philippet P, Waterkeyn C, Otten J for the Children Leukemia Cooperative Group (CLCG) of the European Organization for Research and Treatment of Cancer (EORTC) . Value of high-dose Ara-C during the interval-therapy of a BFM-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the EORTC 58881 randomized phase III trial. (Submitted)
5. Van Der Werften Bosch J, Suciu S, Philippe N, Mazingue F, Vilmer E, Robert A, Mechinaud F, Marguerit G, Lutz P, Ferster A, Boutard P, Brock P, Muntzer M, Michel G, Plouvier E, Rialland X, Thyss C, Waterkeyn C, Solbu G, Otten J . The value of 6-MP i.v. during maintenance treatment in childhood acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL): results of the randomized phase III trial 58881 of EORTC Childhood Leukemia Cooperative Group (CLCG) Blood 1999 94: (Suppl. 1) (Abstr. 2791)